Prendopril Erbumine Tablet

PRINROOT-4

Perindopril Erbumine 4 mg Tablets

Division: DIABGLYM

Composition

Each tablet contains:

Perindopril Erbumine IP — 4 mg

Excipients — q.s.

Colour: Approved colour used

Dosage form: Oral tablet

Product Description

PRINROOT-4 contains Perindopril Erbumine 4 mg, a long-acting angiotensin-converting enzyme (ACE) inhibitor formulated for the effective management of hypertension, heart failure, stable coronary artery disease, and long-term cardiovascular risk reduction. Perindopril provides sustained blood pressure control by inhibiting the renin-angiotensin-aldosterone system (RAAS), promoting vasodilation, reducing cardiac workload, and protecting cardiovascular and renal function.

Perindopril Erbumine is widely prescribed in cardiology, nephrology, and internal medicine for patients with essential hypertension, diabetes-associated hypertension, chronic kidney disease, left ventricular dysfunction, and established cardiovascular disease. It helps reduce blood pressure, improve endothelial function, decrease arterial stiffness, and lower the risk of myocardial infarction, stroke, heart failure progression, and cardiovascular mortality.

PRINROOT-4 is particularly beneficial for patients requiring effective blood pressure control along with cardiovascular and renal protection, making it an important therapy in preventive cardiology and diabetic vascular care.

Technical Knowledge of Perindopril Erbumine

Perindopril is converted in the liver to its active metabolite Perindoprilat, which inhibits angiotensin-converting enzyme. This reduces the formation of angiotensin II, decreases aldosterone secretion, promotes vasodilation, reduces sodium and water retention, improves endothelial function, and enhances arterial compliance.

Perindopril also reduces bradykinin degradation, contributing to improved vascular function and nitric oxide-mediated vasodilation. Its long duration of action provides effective once-daily blood pressure control and sustained cardiovascular protection.

Mechanism of Action

Perindopril inhibits angiotensin-converting enzyme, reduces angiotensin II formation, decreases aldosterone secretion, promotes vasodilation, improves endothelial function, reduces peripheral vascular resistance, decreases cardiac afterload, and provides cardiovascular and renal protection.

Key Benefits

Effective reduction of systolic and diastolic blood pressure

Provides sustained 24-hour blood pressure control

Supports cardiovascular and renal protection

Improves endothelial function

Reduces arterial stiffness

Decreases cardiac workload

Helps prevent cardiovascular events

Suitable for long-term hypertension and cardiovascular management under medical supervision

Clinical Applications

PRINROOT-4 is commonly prescribed for essential hypertension, hypertension with diabetes mellitus, hypertension with chronic kidney disease, heart failure, stable coronary artery disease, left ventricular dysfunction, cardiovascular risk reduction, and long-term antihypertensive management.

Facts About Perindopril Erbumine

Perindopril is an evidence-based ACE inhibitor with extensive clinical research demonstrating significant reductions in cardiovascular morbidity and mortality. It is widely recommended in international hypertension, heart failure, and coronary artery disease guidelines because of its proven benefits in blood pressure control, vascular protection, and prevention of major cardiovascular events.

Key Facts

Long-acting ACE inhibitor

Perindopril Erbumine 4 mg for cardiovascular and renal protection

Provides sustained 24-hour antihypertensive action

Effective in hypertension, heart failure, and coronary artery disease

Supports long-term cardiovascular risk reduction

Evidence-based ACE inhibitor therapy

Quality-assured pharmaceutical formulation

PCD Pharma Franchise Opportunity

PRINROOT-4 is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of hypertension, diabetes, chronic kidney disease, obesity, and cardiovascular disorders creates strong prescription demand and long-term market potential for this formulation.

Why Choose PRINROOT-4 for PCD Pharma Franchise?

High prescription potential

Strong physician and cardiologist acceptance

Attractive monopoly franchise opportunity

Competitive pricing

Promotional support available

Visual aids and marketing inputs

Consistent product quality

Excellent repeat business potential

Third Party Manufacturing

Chemsroot Pharmaceutical offers Third Party Manufacturing of Perindopril Erbumine 4 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses.

Our Third Party Manufacturing Services Include

Private label manufacturing

Contract manufacturing

Custom brand manufacturing

Loan license manufacturing

DCGI-compliant production

GMP-certified manufacturing

Batch manufacturing documentation

Product registration support

Customized packaging and artwork

Monopoly franchise packaging

Bulk manufacturing capability

Manufacturing Features

Pharmaceutical-grade raw materials

IP/BP/USP quality standards

In-process quality control

Finished product testing

Stability-oriented formulation

Moisture-controlled tablet manufacturing

Blister and Alu-Alu packaging options

PRINROOT-4 from DIABGLYM combines effective blood pressure control, comprehensive cardiovascular and renal protection, evidence-based ACE inhibitor therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, nephrologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Perindopril formulation.